PT  - JOURNAL ARTICLE
AU  - Symons, Kent T.
AU  - Nguyen, Phan M.
AU  - Massari, Mark E.
AU  - Anzola, John V.
AU  - Staszewski, Lena M.
AU  - Wang, Li
AU  - Yazdani, Nahid
AU  - Dorow, Steven
AU  - Muhammad, Jerry
AU  - Sablad, Marciano
AU  - Rozenkrants, Natasha
AU  - Bonefous, Celine
AU  - Payne, Joseph E.
AU  - Rix, Peter J.
AU  - Shiau, Andrew K.
AU  - Noble, Stewart A.
AU  - Smith, Nicholas D.
AU  - Hassig, Christian A.
AU  - Zhang, Yan
AU  - Rao, Tadimeti S.
TI  - Pharmacological Characterization of KLYP961, a Dual Inhibitor of Inducible and Neuronal Nitric-Oxide Synthases
AID  - 10.1124/jpet.110.172817
DP  - 2011 Feb 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 468--478
VI  - 336
IP  - 2
4099  - http://jpet.aspetjournals.org/content/336/2/468.short
4100  - http://jpet.aspetjournals.org/content/336/2/468.full
SO  - J Pharmacol Exp Ther2011 Feb 01; 336
AB  - Nitric oxide (NO) derived from neuronal nitric-oxide synthase (nNOS) and inducible nitric-oxide synthase (iNOS) plays a key role in various pain and inflammatory states. KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC50 values 50–400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC50 >15,000 nM). It has ideal drug like-properties, including excellent rodent and primate pharmacokinetics coupled with a minimal off-target activity profile. In mice, KLYP961 attenuated endotoxin-evoked increases in plasma nitrates, a surrogate marker of iNOS activity in vivo, in a sustained manner (ED50 1 mg/kg p.o.). KLYP961 attenuated pain behaviors in a mouse formalin model (ED50 13 mg/kg p.o.), cold allodynia in the chronic constriction injury model (ED50 25 mg/kg p.o.), or tactile allodynia in the spinal nerve ligation model (ED50 30 mg/kg p.o.) with similar efficacy, but superior potency relative to gabapentin, pregabalin, or duloxetine. Unlike morphine, the antiallodynic activity of KLYP961 did not diminish upon repeated dosing. KLYP961 also attenuated carrageenin-induced edema and inflammatory hyperalgesia and writhing response elicited by phenylbenzoquinone with efficacy and potency similar to those of celecoxib. In contrast to gabapentin, KLYP961 did not impair motor coordination at doses as high as 1000 mg/kg p.o. KLYP961 also attenuated capsaicin-induced thermal allodynia in rhesus primates in a dose-related manner with a minimal effective dose (≤10 mg/kg p.o.) and a greater potency than gabapentin. In summary, KLYP961 represents an ideal tool with which to probe the physiological role of NO derived from iNOS and nNOS in human pain and inflammatory states.